Explore the pinnacle of our contributions at ISPOR 2023

Explore the pinnacle of our contributions at ISPOR 2023 Our team presented five cutting-edge research posters that redefine the landscape of healthcare economics and market access. Each poster encapsulates a wealth of insights, innovations, and strategic perspectives crafted by our expert team at GPI. Our posters delve into key themes shaping the future of market…

research-icon

Our team presented five cutting-edge research posters that redefine the landscape of healthcare economics and market access. Each poster encapsulates a wealth of insights, innovations, and strategic perspectives crafted by our expert team at GPI.

Our posters delve into key themes shaping the future of market access, health economics, and outcomes research.

From innovative methodologies to revolutionary findings, we’re charting the course for a dynamic and impactful healthcare ecosystem.

From our experience in data and analytics, gain a global outlook as our posters dissect regional nuances, providing a comprehensive understanding of market dynamics across borders.

We believe in bridging gaps and fostering collaboration for a unified approach to healthcare solutions, where data is at the heart of all these initiatives.

Can machine learning accurately predict payer behaviour?

As machine learning has gained popularity and excitement across many sectors, we investigated whether it could be applied to market access. In this research, we trained and tested the accuracy of machine learning models, when applied to our value-based pricing methodology, to determine the feasibility of predicting payer decisions and prices for a new orphan asset in France, Germany and the UK.

Download the full research here:

Loss of Exclusivity (LoE): Impact analysis across Europe-5 and select Nordic countries

The financial impact of Loss of Exclusivity (LoE) on pharmaceutical companies can be significant and can vary depending on specific drug and market conditions. This research characterise the impact of LoE and company mitigation strategies in 8 European Countries; mainly Europe-5 and Denmark, Sweden, and Norway.

Download the full research here:

Predicting value and price of orphan drugs: a comparison across Europe and the US

Value-based pricing of pharmaceutical products has huge potential within market access and helps payers, pharmaceutical companies and patients by improving healthcare outcomes at an affordable cost. This research aims to determine the accuracy of a value-price model to forecast the price of an orphan product across different payer types; specifically, Italy, Spain and the US.​

Download the full research here:

Assessing the Barriers to Healthcare Resource Use (HRU) Data Collection and Offering Solutions to Support the Evidence Generation Process in LMICs. 

Health care resource use (HRU) data is essential in understanding the budget impact of a product in a market. However, in many low- and middle-income countries sourcing such data remains difficult. This research sought to understand the key barriers in terms of collecting HRU data and potential solutions to overcome these.​

Download the full research here:

Predicting Drug Price Erosion in Germany Associated With Indication Expansion, to Understand the Potential Launch Price Benchmark for a New Product.

For countries which use price benchmarking, understanding the rate of price erosion for existing treatments is crucial to understand the likely launch price of a new product with no additional benefit. This research sought to understand the rate of and driving factors behind price erosion across several analogue products and use these to develop an algorithm to allow us to predict the new price of three treatments following indication expansion.​

Download the full research here:

Share this research: